Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
PharNext
PharNext
Activities:
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Recruitment
Pharnext appoints Amit Kohli as COO
Finance
Pharnext begins partnership with Tasly, Chinese pharma group
Partnership will exploit the potential of modernised Chinese traditional medicine to make new drug combinations
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
French biopharmaceutical firm Pharnext hires two
Niall Murphy as Chief Scientific Officer and Pierre Schwich as Chief Financial Officer
Subscribe now